IPO TABLE: Five biotech offerings coming soon after Affimed priced, eight others filed or set terms
This article was originally published in Scrip
Executive Summary
The market for initial public offerings has been especially frothy for biotechnology companies during the past two years and the week of 15 to 19 September may illustrate perfectly the strange dichotomy at work in the IPO space.
You may also be interested in...
CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Need a specific report? 1000+ reports available
Buy Reports